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1130Objective:Modern series from high-volume esophageal centers report an approximate 40% 5-year survival in
patients treated with curative intent and postoperative mortality rates of less than 4%. An objective analysis of
factors that underpin current benchmarks within high-volume centers has not been performed.
Methods: Three time periods were studied, 1990 to 1998 (period 1), 1999 to 2003 (period 2), and 2004 to 2008
(period 3), in which 471, 254, and 342 patients, respectively, with esophageal cancer were treated with curative
intent. All data were prospectively recorded, and staging, pathology, treatment, operative, and oncologic out-
comes were compared.
Results: Five-year disease-specific survival was 28%, 35%, and 44%, and in-hospital postoperative mortality
was 6.7%, 4.4%, and 1.7% for periods 1 to 3, respectively (P<.001). Period 3, compared with periods 1 and 2,
respectively, was associated with significantly (P<.001) more early tumors (17% vs 4% and 6%), higher nodal
yields (median 22 vs 11 and 18), and a higher R0 rate in surgically treated patients (81% vs 73% and 75%). The
use of multimodal therapy increased (P<.05) across time periods. By multivariate analysis, age, T stage, N
stage, vascular invasion, R status, and time period were significantly (P<.0001) associated with outcome.
Conclusions: Improved survival with localized esophageal cancer in the modern era may reflect an increase of
early tumors and optimized staging. Important surgical and pathologic standards, including a higher R0 resec-
tion rate and nodal yields, and lower postoperative mortality, were also observed. (J Thorac Cardiovasc Surg
2012;143:1130-7)Supplemental material is available online.Earn CME credits at
http://cme.ctsnetjournals.org
The curative approach to esophageal and junctional cancer
is historically associated with poor outcomes, with cure
rates of approximately 20% and a risk of operative morbid-
ity and mortality greater than for any other cancer opera-
tion.1 Of note, several reports from high-volume centers
suggest significant recent advances in outcomes, with
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The Journal of Thoracic and Cardiovascular Surpostoperative mortality of less than 4%.2-4 General factors
that may underpin this improvement include more accurate
staging enabling precise treatment planning, improved
physiologic risk assessment for surgery, advances in perio-
perative care, earlier diagnosis through greater awareness
of Barrett’s esophagus and strict surveillance, lower thresh-
olds for endoscopy, and the use of neoadjuvant and adjuvant
therapies.5-7 The key organizational element underpinning
improved outcomes may be the increasing trend for onco-
logic resections to the domain of specialist high-volume sur-
geons working in multidisciplinary teams in high-volume
hospitals.5,8
The evidence in support of restricting esophageal cancer
surgery to high-volume centers is unassailable, but within
high-volume centers the structure and process factors asso-
ciated with improved oncologic and operative outcomes are
rarely studied. In addition to volume, measures of structure
include specialization, organization, and centralization. Pro-
cess measures include staging, multidisciplinary decision-
making and planning, neoadjuvant and adjuvant therapies,
type of surgery, perioperative care, and pathologic reporting.
The Esophageal and Gastric Cancer Center at St James’s
Hospital in Dublin is a high-volume esophageal center.
The pattern of disease in Ireland, with adenocarcinoma the
most common cancer, is representative of what is observed
in North America andmuch of Europe.6 There is no nationalgery c May 2012
Abbreviations and Acronyms
AEG ¼ adenocarcinoma of the esophagogastric
junction
CT ¼ computed tomography
EUS ¼ endoscopic ultrasound
PET ¼ positron emission tomography
TRG ¼ tumor regression grade
Reynolds et al General Thoracic Surgerycentralization or a national Barrett’s surveillance program.
With no major structural changes, a significant quality
improvement in operative and oncologic outcomes was
nonetheless observed over time, and the aim of this study
was to analyze patterns of care and key factors that may be
associated with the outcomes evident in the current era.G
T
SMATERIALS AND METHODS
Patients attending the Center between 1990 and 2008with a diagnosis of
cancer of the esophagus or esophagogastric junction were included. The
study focused on patients treated with curative intent, defined as pretreat-
ment staging of T0–3, N any, and M0, and considered fit enough to undergo
treatment. Selected patients with cT4 disease were also treated with cura-
tive intent. Adenocarcinoma of the esophagogastric junction (AEG) in-
cluded tumors that had their center within 5 cm proximal or distal of the
anatomic cardia, identified endoscopically, and were classified per the Sie-
wert criteria.9 All data are prospectively recorded in a database (Dendrite,
London, UK). The study was approved by the institutional review board.
Structures
The St James’s Hospital is a high-volume center for esophageal and
junctional cancer operating since the mid-1970s. Surgeons are defined as
upper gastrointestinal surgeons, not thoracic surgeons, and undertake at
minimum 30 major esophageal resections each per annum. The esophageal
program has been aligned with dedicated intensive care specialists and tho-
racic anesthetists throughout the study period.
Process
Computed tomography (CT) of the neck, thorax, and abdomen became
standard in 1995 but was used only sporadically between 1990 and 1995.
The use of 18-F-deoxyglucose positron emission tomography (PET) scans
was introduced in 2003 and has been performed as a combined CT-PET
since early 2006. Endoscopic ultrasound (EUS) was available on an incon-
sistent basis since 1993 and has been routine since 2007 with the appoint-
ment of a dedicated EUS specialist. Laparoscopy is standard for locally
advanced tumors below the diaphragm.
A formal multidisciplinary team was established in 1999, including an
advanced nurse specialist and defined lead clinicians in surgery, medical
and radiation oncology, radiology, pathology, and gastroenterology. A
weekly conference to discuss all new cases has been in place since 1999,
and conference proceedings have been audited since 2004. A weekly
esophageal clinic with attendance by surgeons, nurse specialists, and nutri-
tionists, and same-day linkage to gastroenterology, medical, and radiation
oncologists has been operational since 2004.
Preoperative chemoradiation is the preferred multimodal approach for
patients with predicted locally advanced tumors. A randomized trial of
multimodal therapy versus surgery alone was performed at this center be-
tween 1990 and 1995.6 There have been no changes to the chemoradiation
regimen or dosing schedule over the study period since the time of this trialThe Journal of Thoracic and Carand no other trial performed. Patients with AEG type III tumors have been
considered for postoperative chemoradiation and more recently for pre-
and postoperative chemotherapy.10,11
For surgery, the principle of wide clearance and a radical lymphade-
nectomy is the goal in all cases, with the extent of resection influenced
by the location of the tumor, comorbidities, cardiac and respiratory func-
tion, and local extent of the tumor.12,13 The usual standard for esophageal
tumors is an abdominal–thoracic en bloc esophagectomy. A transhiatal
esophagectomy is considered for patients with clinical T1 and predicted
node-negative disease or for higher-risk operative cases due to age or re-
spiratory comorbidity. For patients with AEG type III tumors, an ex-
tended total gastrectomy and an anastomosis via a transmediastinal
approach or separate thoracotomy is performed. Endoscopic mucosal re-
section was introduced in 2007 and is applied to patients with high-grade
dysplasia or tumors that by EUS assessment do not invade the submucosa
(uT1a).
Patient assessment for fitness for surgery or multimodal therapy has
been largely unchanged since 1990, with the absence of major respiratory
disease being the key clinical criteria, as well as satisfactory pulmonary
function test results (forced expiratory volume in 1 second>1.5 L) and per-
formance status as previously described.13 Thoracic epidurals have been
used since 1992. All patients are extubated immediately postoperatively
and managed in a high-dependency unit or intensive care unit before trans-
fer to a specialist surgical ward. All patients receive early enteral nutrition
via a needle catheter jejunostomy. Perioperative care protocols have been
relatively uniform since 1996 but were not standardized or audited during
this study period. All complications, major and minor, were defined and
prospectively audited, as previously described.13
Pathologic assessment is performed per standard guidelines.14 All mar-
gins (proximal, distal, and circumferential) were assessed, as well as tumor
differentiation, lymphovascular invasion, and perineural invasion. An R1
deep (circumferential) margin denotes tumor within 1 mm of the resection
margin. The database was adapted and retrospectively classified in 2010 to
include the new 7th edition AJCC Cancer Staging Manual N staging clas-
sification for esophageal and junctional tumors.15 In patients treated with
neoadjuvant therapy, the extent of residual carcinoma in the esophagec-
tomy specimen was assigned perMandard and colleagues16: Tumor regres-
sion grade (TRG) 1 represents a complete response; TRG2 represents rare
residual cancer cells scattered throughout the fibrosis; TRG3 represents an
increase in the number of residual cancer cells, but fibrosis still predomi-
nates; TRG4 represents residual cancer cells outgrowing fibrosis; and
TRG5 represents a complete absence of regression.
Patients are followed at the Esophageal Clinic at 3 monthly intervals for
the first year and at 4 to 6 monthly intervals for the subsequent 4 years. All
patients had CT scans in the first and second post-treatment years or as clin-
ically indicated.Statistics
Three time periods were compared: period 1, from 1990, when prospec-
tive records commenced, and a randomized clinical trial (1990–1995), to
1998 inclusive; period 2, from 1999, when a defined multidisciplinary
team was established, with nurse specialization, to 2003; and period 3,
from 2004 to 2008 inclusive, where multidisciplinary team structure was
well established and processes audited. Statistical analysis was performed
using the Statistical Package for the Social Sciences version 16.0 (SPSS
Inc, Chicago, Ill). Continuous variables were compared using unpaired
t tests, and categoric variables were assessed using the chi-square test. Sur-
vival statistics were calculated using the Kaplan–Meier method, and the
log-rank test was used to assess differences in disease-specific survival be-
tween groups. Survival timewas measured from the date of diagnosis to the
date of an event or last follow-up. Independent variables were entered into
a multivariate Cox proportional hazards model with a forward likelihood
ratio selection procedure. A significance level of .05 was used for all anal-
yses, and all P values reported are 2-tailed.diovascular Surgery c Volume 143, Number 5 1131
TABLE 1. Tumor site and morphology in patients treated with curative intent
Time period 1990–1998 1999–2003 2004–2008 P value
Morphology n % n % n %
Adenocarcinoma 271 57.5 154 60.6 222 64.9 .17
Squamous cell 187 39.7 93 36.6 109 31.8
Small cell 2 0.004 2 0.8 4 1.1
Lymphoma 0 0 1 0.4 1 0.3
Other 7 0.015 4 1.5 6 1.9
Missing 4 0.008 0 0 0 0
Tumor site n % n % n %
AEG 271 56.7 154 62.3 222 65.8 .492
SCC lower third 110 23.4 45 18.2 33 10.0
SCC middle third 54 11.5 38 15.4 62 18.7
SCC upper third 23 4.9 10 4.1 14 4.2
AEG junction n ¼ 271 % n ¼ 154 % n ¼ 222 %
AEG type 1 88 39.6 57 37.0 118 53.2 <.001
AEG type 2 91 33.6 54 35.1 51 22.9
AEG type 3 74 27.3 42 27.3 53 23.9
Unspecified 18 6.6 1 0.06 0 0
Barrett’s surveillance 8 3.0 5 3.3 24 10.8 .035
AEG, Adenocarcinoma of the esophagogastric junction.
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Volumes, Pathology, and Treatment Intent
Between 1990 and 2008, 1787 patients were referred
with esophageal or junctional cancer, 704 in period 1,
494 in period 2, and 589 in period 3 (Table E1). The
sex distribution and mean age were similar across the
time periods. There was a significant (P ¼ .003) increase
in the incidence of adenocarcinoma, from 55.5% and
53.2% in periods 1 and 2, respectively, to 62%, in period
3. There was a significant (P<.001) decrease in the per-
centage of patients treated with curative intent, from 68%
in period 1 to 53% and 58% in periods 2 and 3,
respectively.
For patients treated with curative intent (n ¼ 1067), the
tumor site and morphology are shown in Table 1. Adenocar-
cinoma was the dominant pathology in each time period,
with a nonsignificant increase (P ¼ .17) from 57.5% to
60.6% to 64.9% over each time period, respectively.
Within the AEG cohort, AEG type 1 represented 53% in
the most current time period compared with 39.6% in pe-
riod 1 and 37.0% in period 2 (P<.001). In period 3, 24 pa-
tients, representing 10.8% overall and 20.3% of patients
with AEG 1, were on Barrett’s surveillance compared
with 3% overall in the 2 previous time periods.
Staging
Staging modalities in the different periods are shown in
Table E2. In patients treated with curative intent, just
31% of patients underwent CT imaging in period 1, com-
pared with 100% in periods 2 and 3. For PET imaging,
this was performed in 82% of patients in period 3 and
11% in period 2. EUS increased from 10% and 9% in pe-
riods 1 and 2, respectively, to 32% in period 3, and 85%1132 The Journal of Thoracic and Cardiovascular Sursince 2007. Since 2004, 100% of patients treated with cura-
tive intent were discussed at the weekly multidisciplinary
meeting.
Treatment of Patients With Curative Intent
In patients treated with curative intent, there was a signif-
icant (P<.001) decrease in the use of surgery, from 94.6%
in period 1 to 80.7% in period 2 and 71.1% in period 3
(Table 2). A corresponding increased use of radical chemo-
radiotherapy was observed, from 2.5% to 16.1% and
23.4% in periods 1 to 3, respectively. The use of endoscopic
mucosal resection for high-grade dysplasia and uT1a tu-
mors is exclusive to the recent period, representing 5.3%
of operative approaches.
The use of multimodal therapy as a percentage of all sur-
gical approaches increased from 28% in period 1 to 37% in
period 2 and 41% in period 3 (P<.001). In patients under-
going multimodal therapy, a similar percentage did not
progress to surgery in each time period because of progres-
sive disease or worsening performance status (9.4% period
1, 9.6% period 2, and 16% period 3). In period 3, the use of
transhiatal esophagectomy increased, representing 5.8% of
resections, compared with 1.8% in period 1 and 2.4% in
period 2 (P ¼ .027).
Pathologic Stage and Response to Neoadjuvant
Therapy
Surgery-only cohort. The incidence of early esophageal
cancer, defined as cancer confined to the mucosal or submu-
cosa, and including high-grade dysplasia, pT1a, and pT1b,
was 6.6%, 10.0%, and 34.3% (P<.001) in periods 1 to 3,
respectively. pT3 tumors represented 77%, 57%, and 45%
of resections in periods 1 to 3, respectively (Table 3).gery c May 2012
TABLE 2. Treatment details
Time period 1990–1998 1999–2003 2004–2008 P value
Treatment details of patients treated with
curative intent
n ¼ 471 % n ¼ 254 % n ¼ 342 %
Radical chemoradiotherapy 12 2.5 41 16.1 80 23.4 <.001
Surgery: 446 94.6 205 80.7 243 71.1 <.001
Surgery first 320 71.7 130 63.4 131 54 <.001
Multimodal completed 126 28.3 75 36.6 99 40.7 .05
Endoscopic mucosal resection 0 0 13 5.3 .0001
Failed to progress to surgery after multimodal
therapy (of total multimodal therapy)
13 9.4 8 9.6 19 16 NS
Type of surgery
2 Phase esophagectomy 269 60.3 110 53.6 132 54.3 NS
3 Phase esophagectomy 91 20.4 42 20.5 51 21.0
Transhiatal* 8 1.8 5 2.4 14 5.8
Total gastrectomy 37 8.3 34 16.6 22 9.1
Extended proximal gastrectomy 8 1.8 2 1.0 5 2.1
Open/close 2 0.5 2 1.0 5 2.1
PLO 31 7.0 10 4.9 14 5.8
PLO, Pharyngo-laryngo-esophagectomy. *Transhiatal esophagectomy rate P ¼ .027.
Reynolds et al General Thoracic Surgery
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SNode-negative status was evident in 42.3%, 35.7%, and
48.1% for periods 1 to 3, respectively (P ¼ .446). A heavy
nodal burden (N2/N3) was evident in 37% in period 1, 37%
in period 2, and 36% in period 3 (0.546). The R0 resection
rate was significantly (P<.01) improved in periods 2 and 3
compared with period 1.
Multimodal cohort. A complete pathologic response
(TRG1) was observed in 22%, 24%, and 21% of patients
in periods 1 to 3, respectively. A major response (TRG1
and TRG 2) was evident in 49%, 51%, and 46% in pe-
riods 1 to 3, respectively. Node negativity was 71% in pe-
riod 1, 57% in period 2, and 40.4% in period 3 (P<.001).
The R0 resection rate was 81.8% in period 3 compared
with 88.1% and 85.7% in periods 1 and 2, respectively
(P ¼ .427). N2/3 nodal burden represented 12%, 21%,TABLE 3. Pathologic T and N stage: Patients treated with surgery only
Pathology
1990–1998 2003–2008
Surgery n ¼ 320 (%) Surgery n ¼ 130* (%)
HGD/in situ 5 (1.1) 2 (1.5)
T0 0 0
T1 19 (5.5) 11 (8.5)
T2 28 (8.0) 28 (21.5)
T3 254 (77.0) 74 (56.9)
T4 14 15 (11.5)
Nodal status
N0 132 (42.3) 46 (35.7)
N1 65 (20.8) 35 (27.1)
N2 65 (20.8) 30 (23.3)
N3 50 (16.0) 18 (14.0)
R0 resection
R0 232 (73) 98 (75)
R1 87 (27) 32 (25)
HGD, High-grade dysplasia. *Excludes open and close laparotomy and endoscopic muco
The Journal of Thoracic and Carand 30% in periods 1 to 3, respectively (P ¼ .01)
(Table 4).
Nodal Yield and Involvement
For all groups, including surgery and multimodal co-
horts, the median (range) number of nodes harvested was
11 (1–44) in period 1, 18 (4–52) in period 2, and 22
(8–62) in period 3 (P< .05). The percentage of patients
with a nodal yield greater than 15 was 50%, 78%, and
90% in periods 1 to 3, respectively (P<.05).
Operative Outcomes
There were 4 (1.7%) in-hospital postoperative deaths in
period 3, a significant (P< .001) improvement compared
with 30 (6.7%) in period 1 and 9 (4.4%) in period 22004–2008
P valueSurgery n ¼ 131* (%)
5 (3.8) Early cancer rate (Tis/T1/T2)<.001
0
40 (30.5)
22 (16.8)
59 (45.0)
5 (3.8)
63 (48.1) .108
21 (16.0) .082
24 (18.3) .519
23 (17.6) .628
106 (81) P<.05 2004–2008 vs others
25 (19)
sal resection.
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TABLE 4. Pathologic T and N status and response to neoadjuvant treatment: Multimodal treatment group
Pathology
1990–1998 2003–2008 2004–2008
P valueMultimodal n ¼ 126, (%) Multimodal n ¼ 75, (%) Multimodal n ¼ 99, (%)
HGD/in situ 0 0 0 Early cancer rate (Tis/T1/T2)<.001
T0 29 (23) 14 (18.7) 24 (24)
T1 26 (20.6) 16 (19.3) 11 (11)
T2 21 (16.7) 15 (20.0) 17 (17)
T3 47 (37.3) 29 (38.7) 46 (46)
T4 3 (2.4) 1 (0.01) 1 (1)
Nodal status
N0 89 (71.2) 43 (57.3) 40 (40.4) <.001
N1 21 (16.8) 15 (20.0) 29 (29.3) .062
N2 12 (9.6) 10 (13.3) 17 (17.2) .205
N3 3 (2.4) 5 (6.7) 13 (13.1) .01
Response
TRG 1 24 (21.6) 18 (24.3) 21 (21) .521
TRG 2 30 (27.0) 20 (26.7) 25 (25)
TRG 3 23 (20.7) 17 (22.7) 26 (26)
TRG 4 21 (18.9) 17 (22.7) 18 (18)
TRG 5 13 (11.7) 2 (2.7) 9 (9)
Missing 15 1 0
R0 resection
R0 111 (88.1) 64 (85.7) 81 (81.8) .427
R1 15 (11.9) 11 (14.7) 18 (18.2)
HGD, High-grade dysplasia; TRG, tumor regression grade.
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periods in the incidence of pneumonia, anastomotic leaks,
arrhythmias, myocardial infarction, or thromboembolic
events, but the incidence of respiratory failure was signifi-
cantly (P < .05) decreased in period 3 compared with
both other time periods.
Survival
In patients treated with curative intent, the median
disease-specific survival in period 3 was significantly
(P< .05) increased at 33 months compared with 17 and
23 months for periods 1 and 2, respectively (Figure 1). At
a median follow-up of 46 months and a minimum of 24
months, the actuarial 1-, 3-, and 5-year disease-specificTABLE 5. Postoperative morbidity and mortality
Time period
1990–1998
n % n
30-d mortality 24 5.4 5
90-d mortality 6 3
Total in-hospital mortality 30 6.7 9
Respiratory
Pneumonia 74 16.6 21
Respiratory failure 42 9.4 17
Cardiovascular
Atrial fibrillation 32 7.2 13
Myocardial infarction 3 0.006 2
Anastomotic
Radiologic or clinical leak 38 8.5 8
Graft ischemia 5 1.1 1
1134 The Journal of Thoracic and Cardiovascular Sursurvival for period 3 was 80%, 55%, and 44%, respec-
tively. This compares with disease-specific survival of
65%, 36%, and 28% for period 1, and 75%, 43%, and
35% for period 2. The overall 5-year survival for period 1
was 25%, 29% for period 2, and 37% for period 3.
In a univariate analysis of disease-specific survival (Table
E3), age, sex, pT stage, pN stage, number of involved nodes,
R status, venous invasion, and period of treatment were sig-
nificantly (P<.05) associated with survival. In multivariate
analysis, age, nodal status, T stage, and venous invasion
were significant, as well as the time period, with a hazard
ratio of 0.415 (0.315–0.547) for period 3, compared with
0.717 (0.576–0.891) for period 2 and 2.41 (1.829–3.176)
for period 1.1999–2003 2004–2008
P value (c2)% n %
2.4 3 1.3
1
4.4 4 1.7 <.0001
10.2 31 12.8
8.3 9 3.7 <.05
6.3 30 12.3 NS
0.01 4 1.6
3.9 10 4.1 NS
0.5 1 0.4
gery c May 2012
FIGURE 1. Disease-specific survival in patients treated with curative in-
tent. CI, Confidence interval.
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In the modern era, there is a consistent reported trend of
markedly improved operative and oncologic outcomes from
high-volume esophageal programs within academic medi-
cal centers.1-4 The current benchmark survival in patients
treated with curative intent is 35% to 50%, not 20% as
commonly quoted, and postoperative deaths are rare, usu-
ally less than 4%.17,18 The argument in favor of esophageal
cancer being the exclusive domain of high-volume surgeons
in high-volume centers is compelling,9 and there is
evidence from Europe that organizational reform and cen-
tralization of esophageal cancer care may improve out-
comes.19 Within high-volume centers, there is also
evidence of improved outcomes over time, but factors that
underpin such improvement are rarely studied or re-
ported.18,20,21Where significant improvements in oncologic
and operative outcomes occur, does this reflect increased
percentages of patients with early stage disease, improved
staging, better treatment planning, better cancer surgery,
greater use of multimodal approaches, advances in perio-
perative care, a combination of factors, or elements that
cannot easily be measured? In this study of 1067 patients
treated with curative intent, where all operations were
performed by high-volume surgeons in a high-volumeThe Journal of Thoracic and Carcenter, the most recent 5-year period is associated with
markedly improved oncologic and operative outcomes.
An increase in early cancers, the introduction of formal
multidisciplinary processes, improved staging, an increased
use of nonoperative therapies, and improvements in proxy
measures of cancer surgery are all features of the current pe-
riod that may underpin the attainment of improved
outcomes.
A 5-year survival of 44% for the period 2004–2008 is
consistent with other series.2-4 A shift toward early-stage
disease may be central to this finding, which now represents
close to one fifth of patients presenting for curative therapy,
compared with 1 in 20 a decade ago. Adenocarcinoma rep-
resented 38 of 42 early tumors in the recent time period; of
these, 25 (65%) were on Barrett’s surveillance programs. In
a report of 263 patients with adenocarcinoma treated over
a 13-year period by Portale and colleagues2 at the Univer-
sity of Southern California, the overall 5-year survival
was 50%, and pT1N0 represented approximately 50% of
tumors in the final 2 years of the study. In this and our
own series we do not know whether the increase in early
tumors reflects a referral bias to a specialist center or a na-
tional trend consequent on improved awareness of Barrett’s
esophagus and early detection, and this demands further
study. Similar trends internationally may exist for esopha-
geal squamous cell cancer. From amulticenter study in Italy
of predominantly squamous cell cancer, Ruol and col-
leagues21 reported approximately 10% of patients with
T0/T1 tumors in 1980–1987, compared with 15% in
1988–1995, and 28% in 1996–2004, with 5-year survival
of 19%, 23%, and 42%, respectively.
Improved staging represents a key process measure that
has significantly changed over the time periods, enabling
better definition of patient cohorts who can be selected for
treatment with curative intent. The decrease in patients
treated with curative intent compared with the first time pe-
riod suggests that staging and case selection have influenced
decision-making. CT-PET would be expected to identify
5% to 17% of patients whose treatment plan may be altered
compared with CT alone.22 The impact of EUS on the out-
comes observed is unclear. EUS has the greatest value for
staging of early cancer and has been available throughout
each period but underused until 2007. It is now standard
in combination with CT-PET for patients with localized dis-
ease, and in parallel with an increase in early cancer there
has been increased use of EUS in combination with endo-
scopic mucosal resection for microstaging and curative
therapy.
The approach to surgery and its extent did not signifi-
cantly change over successive time periods, although qual-
ity indicators including nodal yield and negative margins
were improved. Transthoracic esophagectomy with abdom-
inal and thoracic lymphadenectomy is the dominant opera-
tion throughout. There is an increasing use of transhiataldiovascular Surgery c Volume 143, Number 5 1135
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an approach that may be associated with lower respiratory
risks compared with open thoracic surgery, and accounted
for 5.4% of surgery in the recent period, compared with
1.7% in period 1 and 2.3% in period 2.18 The use of mul-
timodal therapy significantly increased to 41% in period
3 compared with 27% in period 1 and 36% in period 2.
The same regimen spans the 3 time periods, based on the
randomized trial conducted between 1990 and 1995, and
combines cisplatin and fluorouracil and 40 to 44 Gy radia-
tion therapy.6 Consistent treatment efficacy is shown by
equivalent major (TRG 1 and 2) histomorphologic regres-
sion at the primary site at 48%, 51%, and 45% for periods
1 to 3, respectively. The patterns of care and pathology in-
dicate that the indication for use has changed, consequent
on improved staging and the lack of a randomized trial, sug-
gesting that the use of multimodal therapy in the modern era
in this center is predominantly in patients with predicted lo-
cally advanced disease or node-positive disease. This is
shown by node-positivity rates in 29% of patients in period
1 compared with 40% in period 2 and 60% in period 3 de-
spite a uniform regimen and identical effects at the primary
site. There has also been an increased use of radical radia-
tion therapy in combination with chemotherapy over time,
because a number of recent series suggest that this approach
may be equivalent to approaches involving surgery, partic-
ularly for squamous cell cancers.23
The operative mortality in the recent time period was less
than 2%, consistent with modern benchmarks from large
single-center experience reported in the international litera-
ture, and markedly improved compared with collected se-
ries.1-4 Many factors may be important, including the
improved case selection, selective use of transhiatal esoph-
agectomy or nonoperative approaches for higher-risk pa-
tients, and development of relatively standardized care
pathways in combination with anesthetists, critical care spe-
cialists, cardiologists, and specialist nurses. The lowest re-
ported mortality rate from a large series is from Low and
colleagues4 at the Virginia Mason Medical Center in Seat-
tle, with 1 death in 340 patients (0.3%) in a 17-year series,
results underpinned by standardized clinical pathways. Sev-
eral key elements, including the use of thoracic epidurals,
restricted intraoperative fluid, early mobilization, and en-
teral nutrition, are in place at this center.4 In this current se-
ries, the most significant change is reduced deaths and
reduced respiratory failure, but other major morbidities re-
mained constant, a finding consistent with other series.21
We acknowledge that changes in staging and decision-
making make the time periods not exactly comparable.
Moreover, elements of quality of care are difficult to mea-
sure. The most significant impact on improved outcomes
may be from the surgeons, oncologists, and other specialist
staff working closely together in defined multidisciplinary
teams, a so-called virtuous circle of shared experience.241136 The Journal of Thoracic and Cardiovascular SurThis philosophy, focus, and drive are embedded widely in
modern multidisciplinary care in cancer and complex sur-
gery, and although these are nuanced and difficult to mea-
sure, they are likely to be a key factor where major
quality improvements are observed.24 We suggest that the
modern high-volume esophageal cancer program targets
stage for stage cure rates consistent with the best reported
benchmarks, and the avoidance of any postoperative death,
and that this philosophy is the driving force in most high-
volume centers dealing with esophageal or other complex
cancers or surgery.25CONCLUSIONS
This study addressed factors that may relate to a continu-
ously evolving improvement in oncologic and operative
outcomes in a high-volume center where adenocarcinoma
is the dominant cancer and the lessons learned may apply
to similar centers in the West. A marked increase in early
cancers is likely to be a key factor, as well as improved clin-
ical and pathologic staging, and the integration of the
multidisciplinary team. The modern team has a shared com-
mitment to standardized care pathways and a drive to avoid
any postoperative death and achieve adequate nodal harvest
and negative margins, and all these factors are likely to af-
fect this encouraging trend.
The authors thank Dr Ewout Courrech Staal for reviewing the
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TABLE E1. Demographics: All patients
Time period
1990–1998 1999–2003 2004–2008
P valuen ¼ 704 % n ¼ 494 % n ¼ 589 %
Mean age (range) 64 y (28–86 y) 62 y (26–83 y) 65 (36–86 y) NS
Male:female ratio 2:1 2:1 2.2:1 NS
Pathology .003
Adenocarcinoma 391 55.5 263 53.2 365 62
Squamous cell 293 41.6 221 44.9 196 33.3
Other 21 3 10 2 28 4.8
Treatment intent: <.05
Curative 471 68 254 53 342 58
Palliative 233 32 240 47 247 42
TABLE E2. Staging and radiologic investigations
1990–1998 1999–2003 2004–2008
P value (c2)n % n % n %
Total patients staged 704 494 589
CT scan 165 23.4 467 94.5 579 98.3 <.001
PET scan/CT-PET 0 0 33 6.7 399 67.7 <.001
EUS 66 9.4 27 5.5 106 18.0 <.001
Barium study 348 49.4 130 26.3 69 11.7 <.001
Total patients treated with curative intent 471 254 342
CT scan 145 30.8 254 100 342 100 <.001
PET scan/CT-PET 0 0 30 11.8 296 86.5 <.001
EUS 50 10.6 24 9.5 105 30.7 <.001
Barium study 257 54.6 64 25.1 36 10.5 <.001
CT, Computed tomography; EUS, endoscopic ultrasound; PET, positron emission tomography.
TABLE E3. Univariate and multivariate analysis of disease-specific survival of patients treated with curative intent
Factor
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Sex (male vs female) 1.208 (1.025–1.423) .024 1.258 (1.036–1.527) .05
Age at diagnosis (>70 vs<70 y) 1.017 (1.009–1.024) <.001 1.017 (1.008–1.026) <.001
Adenocarcinoma 1.05 (0.90–1.224) .536 Not in model
Node negative versus node positive 0.445 (0.379–0.552) <.001 0.461 (0.379–0.561) <.001
T1 vs T2/3 0.395 (0.324–0.483) <.001 0.521 (0.415–0.655) <.001
R0 resection 0.505 (0.417–0.61) <.001 0.706 (0.572–0.87) .001
Neoadjuvant treatment (yes) 0.858 (0.726–1.015) .074 Not in model
Did not undergo resectional surgery 1.449 (1.197–1.755) <.001 n/a
Postoperative complications (yes) 0.916 (0.785–1.069) .265 Not in model
Junction tumor (yes) 0.986 (0.843–1.152) .855 Not in model
Lymphatic invasion 2.46 (2.053–2.947) <.001 c2 ¼ 0.573 .484
Venous invasion 1.49 (1.195–1.857) <.001 1.445 (1.117–1.868) .005
Perineural invasion 1.47 (1.177–1.836) .001 c2 ¼ 0.49 .484
Time period of surgery: for trend <.001 <.001
1990–1998 vs others 1.457 (1.209–1.757) <.001 2.41 (1.829–3.176) <.001
1999–2003 vs others 0.819 (0.68–0.986) .035 0.717 (0.576–0.891) .003
2004–2008 vs others 0.686 (0.569–0.827) <.001 0.415 (0.315–0.547) <.001
CI, Confidence interval.
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